Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Cymbalta Approval Timeline In Doubt After Delay In Second NDA

Executive Summary

Lilly's plans to launch Cymbalta at the start of 2004 appear to hinge on the company's ability to convince FDA that the drug interaction issues delaying approval of duloxetine for incontinence should not hold up availability of the drug for depression
Advertisement

Related Content

Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA
Cymbalta Labeling Hints At Side Effect Claim; Lilly Will Test In Phase IV
Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer
Duloxetine’s Dual Names: Lilly Wants Yentreve As Incontinence Brand
Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small
Lilly Cymbalta manufacturing remains delayed
October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action
Wyeth Allocates Prempro/Premarin Inventories; Stocking Too High, Firm Says
Lilly Outlook For Rx: Political Pressure Will Stay, So Will Double-Digit Growth
Lilly Cymbalta Halted By GMP Issues; “Approvable” Letter Issued Sept. 13
Advertisement
UsernamePublicRestriction

Register

PS042429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel